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Abstract
Background: Several systemic treatments have been shown to increase survival for patients with metastatic
castration-resistant prostate cancer. This study sought to characterize variation in use of the six “focus drugs”
(docetaxel, abiraterone, enzalutamide, sipuleucel-T, radium-223, and cabazitaxel) that have been approved by the
Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer during the years
2010–2015. We hypothesized that the use of these treatments would vary over time and by region of the country.
Methods: We used Clinformatics DataMart™ Database (OptumInsight, Eden Prairie, MN), a de-identified claims database
from a national insurance provider. Our sample included patients with prostate cancer who received any of the six
drugs. We describe changes in usage patterns over time and geographic region of the United States via detailed
descriptive statistics. We explore both patterns of first line therapy and sequence of treatments in our database.
Results: Our final analysis included 4275 patients with a mean age of 74 years. Docetaxel was the most commonly used
first-line therapy in 2010 (97%), 2011 (66%), and 2012 (49%). Abiraterone was the most commonly used first-line therapy
in 2013 (56%), 2014 (46%), and 2015 (34%). Approximately 14% of our study cohort received ≥3 of the 6 drugs
throughout their disease course. There was marked geographic variation in use of each of the drugs.
Conclusion: Variation in treatment patterns were found with respect to both time and geographic location. Prescription
rates of abiraterone outpaced docetaxel as the most commonly prescribed drug after 2013 when it became widely
available. However, some regions of the country still lagged behind and prescribed less than would be expected.
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Background
Prostate cancer, one of the leading causes of cancer
death in men in the United States, is treated with andro-
gen deprivation therapy (ADT) in its advanced form of
metastatic disease [1]. Most patients with metastatic
prostate cancer will require additional treatments
beyond ADT when their cancer progresses to castration-
resistant disease, the lethal form of prostate cancer. The
Food & Drug Administration (FDA) approved docetaxel
in 2004 for the treatment of patients with metastatic
castration-resistant prostate cancer (mCRPC) based on
its ability to improve overall survival [2]. Since 2010, five
new therapies have been FDA-approved to treat patients
with mCRPC. Sipuleucel-T and cabazitaxel were each
approved in 2010 [3, 4]. Abiraterone and enzalutamide
were approved in 2011 and 2012, respectively, [5–8] and
most recently, radium-223 was approved in 2013 after
showing an improvement in overall survival in men with
symptomatic bone metastases [9].
Due to the rapid emergence of these new therapies,
which we refer to as our “focus drugs,” little is known
about their adoption since approval and there is limited
guidance on their use. Importantly, with the exception
of docetaxel, the average wholesale price for each of
these medications is greater than $8000 a month and in-
surance coverage for these treatments are included
under different forms of payment structures within
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payer programs. Abiraterone and enzalutamide are rela-
tively well tolerated oral medications and are typically
covered through prescription drug plans with patient co-
payments and without direct office reimbursements.
Docetaxel and cabazitaxel are associated with greater
side effects and are therefore more difficult for some
patients to tolerate but are covered in a different part of
the health plan and may cost less to patients out of
pocket due to lack of co-payments. Similarly, radium-
223 and sipuleucel-T are not chemotherapy agents but
are delivered intravenously and require specialized
centers to administer. Therefore, use is likely to be influ-
enced by whether a practice invested in the infrastruc-
ture needed to deliver these specialty medications (for
example, radium-223 requires existence of a nuclear
medicine facility).
To better understand the real-world use of these treat-
ments, we sought to characterize initial treatment pat-
terns of the six focus drugs subsequent to FDA-approval
in a large sample of patients with prostate cancer cov-
ered by a national private insurance provider. We
expected that adoption of all of the focus drugs, except
docetaxel, would gradually increase with time after
FDA-approval and that the use of docetaxel would con-
sequently decline as the newer agents were substituted
for docetaxel. We expected that the oral medications
(abiraterone and enzalutamide) would gradually outpace
intravenous medications despite the decreased revenue
to practices since they can be more widely prescribed by
physicians and allow some physicians without access to
infusion centers or tertiary care centers to keep their
patients for longer. However, we expected to see geo-
graphical differences in adoption of the newer agents
with a preference in rural communities for oral therapies
due to difficulty in frequent travel required for intraven-
ous chemotherapy. We also hypothesized that many
patients would be prescribed more than one drug at a
time despite the lack of evidence for benefit for combin-
ation therapy. We use the claims database of a large
national insurance provider to explore these hypotheses.
Methods
Data source
Data for this study was obtained from the Clinformatics
Data Mart (CDM), a de-identified database (OptumIn-
sight, Eden Prairie, MN) from a large, national US health
insurer. This database includes administrative health
claims data of approximately 61 million unique patients
across the United States, including enrollment records,
medical claims, and prescription claims, from 2001 to
the latest data available (currently June 2015). Among
patients 65 years of age and older, three quarters of pa-
tients in the OptumInsight database have Medicare Ad-
vantage plans while the rest are enrolled through private
insurance plans. The database is updated every six to
twelve months, and each member is assigned one unique
identification number regardless of a break in coverage.
Participants and sample selection
To identify patients with prostate cancer in the Optu-
mInsight Claims Database (OCD), the diagnosis fields
(DIAG1 – DIAG5) within the medical claims data were
matched against 185, the International Statistical Classi-
fication of Diseases and Related Health Problems (ICD)
9-CM for a prostate cancer diagnosis. Patients with a
185 diagnosis during the study period of January 1, 2010
to June 30, 2015 who received one of the six focus drugs
were included. To identify patients who received any of
the focus drugs, we matched national drug codes
(NDC), brand names and Healthcare Common Proced-
ure Coding System (HCPCS) codes associated with the
six focus drugs against appropriate fields within the
medical claims and pharmacy claims data. Patient demo-
graphic variables such as age, race, geographic location,
and education level are available by matching on patient
identification numbers across data files. In order to be
considered for analysis of drug treatment patterns and in
order to identify “first drug” for patients with advanced
prostate cancer, we further required continuous enroll-
ment of 180 days prior to receipt of one of the focus
drugs (abiraterone, enzalutamide, docetaxel, cabazitaxel,
sipuleucel-T, or radium-223), with no claim for one of
the six drugs during that 180 days. Continuous enroll-
ment was defined as less than 30 days break in coverage.
In order to identify patients who had metastatic disease,
the following ICD-9-CM codes were included: 196.x,
197.x, 198.x, 198.80, 198.81, 198.82, and 198.89. We
refer the reader to the Additional file 1: supplementary
materials for a detailed description of our sample selec-
tion methods.
Statistical analysis
For each patient in our cohort, we identified pharmacy
and medical claims for the six focus drugs over follow-
up periods. Among these claims, we defined first-line
therapy for each patient as the focus drug associated
with the first claim with respect to time. We construct
line plots of therapy administration rates and first-line
therapy administration rates stratified by year to observe
temporal patterns in treatment. In addition, we calculate
95% confidence intervals (based on the Wilson estimate)
for the first-line therapy administration rates by year and
tabulate the claims by therapy and year. To test for
geographical variation in treatment, we carried out a
chi-squared test of independence between first-line of
therapy and geographical region.
To identify patients who received more than one drug
concurrently, we implemented a search algorithm to find
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therapy sequences containing at least two overlapping
sequences that met the following criteria: a claim for a
focus drug is registered between two claims for a differ-
ent focus drug, the difference between the two claims
being no more than five weeks apart. We carried out a
sensitivity analysis to the choice of “five weeks” as a time
window to assess the robustness of our findings.
Results
We identified 295,525 patients with prostate cancer over
the study period January 1, 2010 to June 30, 2015 and
5659 patients who received one of the six focus drugs
during that time. The final study cohort of patients in-
cluded 4275 patients who were continuously enrolled for
180 days before receipt of first focus drug. The mean
age of patients was 74 (standard deviation, S.D. 9).
Further descriptive characteristics can be found in
Table 1. All variables were significantly different in dis-
tribution (p < 0.05) between the larger prostate cancer
sample and our selected sample of patients who received
any one of the focus drugs. Age, education level, house-
hold income, region, insurance product, and presence of
metastatic disease were strongly significant (p < 0.001)
due to the large sample size. However, observed differ-
ences among some of these variables across the two
groups may not be practically relevant.
Figure 1 illustrates a time indexed plot of the propor-
tion of patients in our sample that received each drug as
first-line therapy in a given year and the most commonly
prescribed first-line drugs. Docetaxel was the most com-
mon first-line therapy in 2010 (97.1%), 2011 (66.0%),
and 2012 (48.9%). Abiraterone was the second most
common first-line therapy in 2011 (24.5%) and 2012
(31.8%), but became the most commonly prescribed
first-line therapy in 2013 (56.3%), 2014 (45.8%), and
2015 (34.2%). In contrast to the oral agents, abiraterone
and enzalutamide, the usage of sipuleucel-T did not rap-
idly increase over time despite FDA-approval in 2010.
Details for each drug frequency can be found in Table 2.
We were able to determine the total number of dis-
tinct focus drugs that a patient received throughout their
course of treatment for patients who started their first
treatment in a given year. In 2011, 57.3% (n = 377) of
patients received one therapy over the course of treat-
ment and 42.7% (n = 281) received at least two. The pro-
portion of patients receiving more than one drug
throughout their course of treatment increased for those
patients who started a drug in 2012; 50.4% (n = 403) of
patients who started a treatment in 2012 received one
therapy over the course of treatment, 48.6% (n = 397)
went on to receive more than one focus drug during
treatment and 21.4% (n = 170) received at least three.
The majority of these drugs were given sequentially and
not concurrently. We only report the frequencies for
2011 and 2012 since follow-up is shorter for patients
who started therapy after 2012. There were 88 patients
identified who received more than one of the six focus
drugs concurrently; Fig. 2 illustrates claims patterns for
50 randomly selected patients who received more than
one of the six focus drugs concurrently during follow-
up. The most common combination was docetaxel plus
either abiraterone (19%) or enzalutamide (10%).
Sipuleucel-T plus either abiraterone (10%) or enzaluta-
mide (11%) was also seen as well as radium-223 plus
abiraterone (8%) or enzalutamide (13%). We also
observed two patients who received three drugs concur-
rently (one patient received abiraterone, enzalutamide,
and docetaxel concurrently; one patient received abira-
terone, enzalutamide, and cabazitaxel concurrently).
We were able to demonstrate administration rates of
the focus drugs as first-line therapy by geographic div-
ision in 2014, the first year that all focus drugs were
FDA-approved for their most updated indication. These
rates are shown in Table 3. Figure 3 illustrates the
expected versus the observed counts under the assump-
tion of independence between therapy and geographic
division. The calculation of the expected frequency takes
into account the distribution of patients included across
different geographical regions. A chi-squared test yielded
a p-value < 0.001, indicating evidence supporting a
difference in administration rates across regions. For
example, the average rate of use for abiraterone as a
first-line therapy in 2014 was 45.8%. However, among
patients in our cohort belonging to the Pacific division
(AK, CA, HI, OR and WA), 61.9% of patients received
abiraterone as a first-line therapy in 2014 in contrast to
26.7% of patients belonging to the West North Central
division (IA, KS, MN, MO, NE, ND, and SD), indicating
significant geographic regional differences in preference
for first-line therapy in 2014.
Discussion
This study found that the most common treatment pre-
scribed between 2010 and 2015 among the six novel
agents for advanced prostate cancer was abiraterone.
Notable temporal patterns emerged throughout the
observed period, including the declining preference of
docetaxel as first-line treatment over time, likely a con-
sequence with the approval of abiraterone in 2011, and a
decline of abiraterone use when enzalutamide was
FDA-approved toward the end of 2012. These patterns
indicate a potential substitution effect of abiraterone for
docetaxel and later enzalutamide for abiraterone. We
would expect with longer times on the market, the fre-
quency of use of abiraterone and enzalutamide may
begin to mirror the therapy that is preferred by patients
and providers as first-line treatment rather than being
driven by the timing of FDA-approval of treatments.
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Table 1 Patient Characteristics
n = 4275 N = 295,525
Variable Mean ± SD/Count (%) Mean ± SD/Count (%)
Age 73.7 ± 9.2 71.1 ± 9.8
Race
White 3001 (70.2) 208,702 (70.6)
Black 553 (12.9) 33,282 (11.3)
Hispanic 324 (7.6) 23,328 (7.9)
Asian 84 (2.0) 6144 (2.1)
Unknown 313 (7.3) 24,069 (8.1)
Education level
Less than 12th grade 32 (0.7) 1681 (0.6)
High school diploma 1223 (28.6) 82,070 (27.8)
Less than bachelor degree 2238 (52.4) 153,094 (51.8)
Bachelor degree plus 599 (14.0) 42,997 (14.5)
Unknown 183 (4.3) 15,683 (5.3)
Household income range
< 50 k 1544 (36.1) 93,629 (31.7)
50 k-99 k 1312 (30.7) 90,934 (30.8)
> 100 k 837 (19.6) 70,373 (23.8)
Unknown 582 (13.6) 40,589 (13.7)
Geographic Region*
New England 203 (4.7) 15,488 (5.2)
Middle Atlantic 299 (7.0) 25,371 (8.6)
South Atlantic 950 (22.2) 71,420 (24.2)
East North Central 567 (13.3) 38,633 (13.1)
East South Central 131 (3.1) 9677 (3.3)
West North Central 448 (10.5) 27,567 (9.3)
West South Central 421 (9.8) 27,438 (9.3)
Mountain 441 (10.3) 27,673 (9.4)
Pacific 628 (14.7) 35,722 (12.1)
Unknown 187 (4.4) 16,536 (5.6)
Product
HMO 2079 (48.6) 121,353 (41.1)
PPO 547 (12.8) 39,180 (13.3)
Other 1649 (38.6) 134,955 (45.7)
Unknown 0 (0.0) 37 (0.0)
Metastatic
Yes 3446 (80.6) 17,802 (6.0)
No 829 (19.4) 277,723 (94.0)
SD, standard deviation; k, one thousand dollars; HMO, health maintenance organization; PPO, preferred provider organization; ASO, administrative services only (self-
funded health plan)
*States within each geographic region:
• New England: Connecticut, Maine, New Hampshire, Rhode Island, Vermont, Massachusetts
• Middle Atlantic: New Jersey, New York, Pennsylvania
• South Atlantic: Delaware, Washington D.C., Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia
• East North Central: Illinois, Indiana, Michigan, Ohio, Wisconsin
• East South Central: Alabama, Kentucky, Mississippi, Tennessee
• West North Central: Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota
• West South Central: Arkansas, Louisiana, Oklahoma, Texas
• Mountain: Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming
• Pacific: Alaska, California, Hawaii, Oregon, Washington
Study cohort (n = 4275) and all patients with prostate cancer (N = 295,525) over the study period. Baseline characteristics for the study cohort were observed at time
of initiation of first-line therapy. Baseline characteristics for the cohort of all patients with prostate cancer were observed at time of first medical claim for prostate
cancer during the study period. Patients were classified as metastatic if a medical claim with ICD-9 codes 196.x, 197.x, 198.x, 198.80, 198.81, 198.82, and 198.89 were
observed at any point during follow up
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Even though the adoption of the oral agents increased
with time, as we predicted, we were surprised that the
use of sipuleucel-T and radium-223 did not increase the
longer they were available despite clinical trials showing
excellent tolerance of therapy. This could be due to the
more complicated administration of those treatments.
Another observation we made was that there was a sub-
stantial number of patients we identified who were
prescribed more than one focus drug concurrently, a
practice that is not evidence-based and may be associ-
ated with unexpected side effects as well as high costs.
What is perhaps more unsettling is that our observation
of frequency of concurrent use is likely to be an under-
estimation of the actual frequency of this practice con-
sidering our strict criteria for identifying concurrent use
of therapies. Finally, we observed significant variation in
regards to adoption of these agents by region of the
country. Some regions appeared to favor intravenous
agents and some the oral agents as first-line treatment.
There were also regions of the country that used a
higher than expected rate of sipuleucel-T and radium-
223 while others used lower than expected rates.
This the first study to our knowledge that describes
the contemporary treatment patterns for advanced pros-
tate cancer and includes all six focus drugs in a large
cohort of patients. Most standard clinical trials do not
investigate drug sequences within the same trial but tend
to focus on one medication. Large observational studies
done with large databases allow the investigation of
several patterns of drugs manufactured by different
pharmaceutical companies in concert. This enables com-
parison of not just one drug but of the entire drug
sequence and in the future, potential outcomes corre-
sponding to those different drug sequences. Some stud-
ies have shown emerging practice patterns for systemic
therapy in patients with mCRPC, such as medical oncol-
ogists prescribing more oral therapy and chemotherapy
than urologists, [10] and evidence that prescriptions for
abiraterone and enzalutamide vary geographically across
the United States [11]. However, comparable studies
demonstrating variation among all six focus drugs and
relative variation in large datasets are lacking. While the
temporal variation that we observed was somewhat ex-
pected as the use of a drug increases from the time a
drug is introduced, the rate of change was not the same
for each treatment. Moreover, there are no data in the
literature with concrete evidence of the temporal changes.
The geographic variation was also important to illustrate.
Geography is a non-clinical factor that has been shown in
the literature to influence variation in health care practices
in several conditions, including treatment of back pain,
[12] tonsillectomy, [13] and other surgical and cardiac
procedures, [14] but has not been described in the
systemic treatment of advanced prostate cancer. While
Fig. 1 Title. Rates of Therapy Use. The top panel shows administration
rates of the different therapies over years 2010 through mid-2015, defined
as the proportion of patients who received that drug at some point in
that year out of all patients who received any of those drugs that year.
Rates were calculated for each drug for each year. The bottom panel
shows administration rates of first-line therapy among the same cohort of
patients, defined as the proportion of patients who received the drug as
first-line therapy out of all patients who received a drug in that year.
Administration rates of first-line therapy should sum to 100% in each year.
The timeline below the two plots illustrates the approximate date at
which each treatment was first approved for use in metastatic castration-
resistant prostate cancer by the Food and Drug Administration (FDA).
Docetaxel was approved in 2004 which is earlier than the timeline can
demonstrate, but the other five treatments have a mark at the approximate
point in time they were first approved
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Table 2 Frequency distribution of first-line therapy
Therapy/Year 2010 2011 2012 2013 2014 2015 All
Docetaxel 374 434 391 207 255 137 1798
97.1% 66.0% 48.9% 22.6% 24.4% 29.0% 42.1%
(95.0, 98.4) (62.3, 69.5) (45.4, 52.3) (20.1, 25.5) (21.9, 27.1) (25.1, 33.2) (40.6, 43.5)
Cabazitaxel 7 9 7 3 4 3 33
1.8% 1.4% 0.9% 0.3% 0.4% 0.6% 0.8%
(0.9, 3.7) (0.7, 2.6) (0.4, 1.8) (0.1, 1.0) (0.1, 1.0) (0.2, 1.8) (0.6, 1.1)
Sipuleucel-T 4 54 120 110 98 30 416
1.0% 8.2% 15.0% 12.0% 9.4% 6.3% 9.7%
(0.4, 2.6) (6.3, 10.6) (2.7, 17.6) (10.1, 14.3) (7.8, 11.3) (4.5, 8.9) (8.9, 10.7)
Radium-223 0 0 0 2 12 18 32
0.0% 0.0% 0.0% 0.2% 1.1% 3.8% 0.7%
(0.0, 1.0) (0.0, 0.6) (0.0, 0.5) (0.1, 0.8) (0.7, 2.0) (2.4, 5.9) (0.5, 1.1)
Abiraterone 0 161 254 515 479 162 1571
0.0% 24.5% 31.8% 56.3% 45.8% 34.2% 36.7%
(0.0, 1.0) (21.3, 27.9) (28.6, 35.1) (53.1, 59.5) (42.8, 48.9) (30.1, 38.6) (35.3, 38.2)
Enzalutamide 0 0 28 77 197 123 425
0.0% 0.0% 3.5% 8.4% 18.9% 26.0% 9.9%
(0.0, 1.0) (0.0, 0.6) (2.4, 5.0) (6.8, 10.4) (16.6, 21.3) (22.3, 30.1) (9.1, 10.9)
Total 385 658 800 914 1045 473 4275
Frequency distribution of first-line therapy among 4275 patients who have a diagnosis of prostate cancer and received one of the listed focus drugs during the
study period, stratified by year. Column percents and 95% confidence intervals (in parentheses) are also provided. Of note, data from 2010 to 2014 include the
entire year, but data from 2015 is for only six months, January 1, 2014 through June 30, 2015


















Fig. 2 Treatment Patterns. Treatment patterns for 50 randomly selected patients who were identified to have received at least two distinct therapies
concurrently during follow-up. Each horizontal row of circles represents one patient and each colored circle represents a claim for a drug for that patient.
For example, the first patient listed at the top of the figure appears to have received 7 claims for abiraterone over a period of several months, but also
received three claims for sipuleucel-T at some point during the time they were also undergoing treatment with abiraterone
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geographic variation may be an independent contributor
to variation, geographic variation in treatment patterns
may be a result of other factors associated with geography,
such as rural/urban differences, patient income, race, and
health system factors.
Another potential contributor to geographic variation
that has not been well-described in prostate cancer
treatment may result from physicians and hospitals.
Physicians from different specialties (e.g. medical oncol-
ogy and urology) treat patients with advanced prostate
cancer, and therefore different guidelines and national
organizations are involved in guideline recommenda-
tions [15, 16]. Physician practices may get reimbursed
higher for intravenous chemotherapy as opposed to oral
medications that are dispensed through pharmacies, and
whether a practice has invested in the infrastructure
necessary to deliver specialty medications such as
sipuleucel-T or radium-223 is likely to affect referral for
these two treatments. Literature has shown that urology
practices invested in radiation technology are more likely
to treat patients with radiation than practices that do
not, even in patients with a low likelihood of benefit
from definitive treatment [17]. In addition, considering
the high cost of treatment options for mCRPC, financial
considerations for the patient become important factors
as well. Some patients have tremendous out of pocket
expenditures for certain treatment options that can lead
to significant financial toxicity, despite the fact that they
may have insurance coverage [18–20]. Except for doce-
taxel, each of the studied agents has an average whole-
sale price of at least $8000 a month and different
insurance plans have varying coverage and co-pays for
medications that are administered intravenously versus
oral drugs. Thus, the out-of-pocket costs for oral drugs
Table 3 Observed versus expected receipt of focus drug in 2014
Region Docetaxel (%) Cabazitaxel (%) Sipuleucel-T (%) Radium-223 (%) Abiraterone (%) Enzalutamide (%) Row Total
New England 12 (27.3) 0 (0.0) 3 (6.8) 0 (0.0) 22 (50.0) 7 (15.9) 44
11 0 4 1 20 8
Middle Atlantic 23 (21.5) 0 (0.0) 6 (5.6) 3 (2.8) 50 (46.7) 25 (23.4) 107
26 0 10 1 50 20
South Atlantic 44 (26.0) 0 (0.0) 20 (11.8) 2 (1.2) 70 (41.4) 33 (19.5) 169
41 0 16 2 78 32
East North Central 38 (22.0) 3 (1.7) 17 (9.8) 2 (1.2) 73 (42.2) 40 (23.1) 173
42 0 16 2 79 33
East South Central 5 (14.7) 0 (0.0) 4 (11.8) 0 (0.0) 19 (55.9) 6 (17.6) 34
8 0 3 0 16 6
West North Central 39 (45.3) 0 (0.0) 12 (14.0) 3 (3.5) 23 (26.7) 9 (10.5) 86
21 0 8 1 39 16
West South Central 20 (21.1) 0 (0.0) 9 (9.5) 1 (1.1) 46 (48.4) 19 (20.0) 95
23 0 9 1 44 18
Mountain 26 (21.1) 0 (0.0) 13 (10.6) 0 (0.0) 64 (52.0) 20 (16.3) 123
30 1 12 1 56 23
Pacific 23 (15.6) 0 (0.0) 5 (3.4) 0 (0.0) 91 (61.9) 28 (19.0) 147
36 1 14 2 67 28
Unknown 25 (37.3) 1 (1.5) 9 (13.4) 1 (1.5) 21 (31.3) 10 (14.9) 67
16 0 6 1 31 13
Column Total 255 4 98 12 479 197 1045
States within each geographic region:
• New England: Connecticut, Maine, New Hampshire, Rhode Island, Vermont, Massachusetts
• Middle Atlantic: New Jersey, New York, Pennsylvania
• South Atlantic: Delaware, Washington D.C., Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia
• East North Central: Illinois, Indiana, Michigan, Ohio, Wisconsin
• East South Central: Alabama, Kentucky, Mississippi, Tennessee
• West North Central: Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota
• West South Central: Arkansas, Louisiana, Oklahoma, and Texas
• Mountain: Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming
• Pacific: Alaska, California, Hawaii, Oregon, Washington
Number of patients (percent) in our study cohort who received the indicated focus drug as first-line therapy by geographic region in 2014 on the top line and
number of patients expected to have received the indicated focus drug as first-line of therapy under the assumption of independence between geographic region
and focus drug are also provided on the second line of each cell
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may be substantially higher than that for chemotherapy
and thus income level is likely to factor in to treatment
decisions. We expect to further evaluate these important
non-clinical variables and their influence on treatment
patterns in future studies. However, the most important
first step was to define the landscape of treatment
patterns adopted over time.
Due to the nature of observational research, there
were limitations inherent to analyzing data using a large
medical claims database such as accounting for missing
or unknown variables. Table 1 demonstrated that the
variables we describe had very few unknown values and
thus we do not expect this small number to substantially
impact our results. Second, a limitation in identifying
our cohort was ensuring that patients who had a diagno-
sis of prostate cancer received one of the focus drugs for
prostate cancer rather than for another diagnosis. Since
docetaxel is the only focus drug in our study that is ap-
proved for use in other cancers and is typically a salvage
treatment in other cancers, we expect that observations
of patients using docetaxel for other cancers concurrent
with a prostate cancer diagnosis will be uncommon and
thus not influence the results substantially. Third, there
were limitations in identifying treatment codes since
reporting of some treatment codes can be delayed. To
handle this limitation, we developed an algorithm based
on timing of administration and cost of drug that is ex-
plained in our Additional file 1: Supplementary Materials
for sample selection. Fourth, the database does not
include information about denied claims so it is difficult
to know if denials factored into observed patterns of
treatments. To address this limitation, we obtained the
Coverage Summary and Policy Guidelines for the private
insurer which included all of our focus drugs as covered
treatments and did not differentiate coverage based on
Local Coverage Determinations. Thus, we expect there
would not have been a systematic denial of coverage for
any of the included treatments and the majority of the
geographic variation we detected is likely due to other
factors such as patient, provider, or hospital factors,
rather than claim denials. We expect that among
patients included in OptumInsight who are all insured
by the same private insurer, coverage for certain treat-
ments are similar across the country. And finally, an-
other limitation was in regards to generalizing the
results of an insured cohort of patients to a broader
population of patients, which is an inherent limitation to
working with a dataset that is limited to patients who
are privately insured. While our results may not be
generalizable to uninsured patients, results are likely to
Fig. 3 Observed versus expected use of therapies by region. Observed number of patients (blue) who received the indicated drug as first-line of therapy
and number of patients expected (red) to have received the drug as first-line, by geographic division, in 2014. Expected numbers are calculated under the
assumption of independence between geographic division and focus drug and account for the fact that there are differing numbers of patients enrolled
in different regions. The category “Other” includes sipuleucel-T, radium-223, and cabazitaxel. NE, New England; MA, Middle Atlantic; SA, South Atlantic; ENC,
East North Central; WNC, West North Central; WSC, West South Central; M, Mountain; PAC, Pacific; UNK, Unknown. States within each geographic region:
New England: Connecticut, Maine, New Hampshire, Rhode Island, Vermont, Massachusetts. Middle Atlantic: New Jersey, New York, Pennsylvania. South
Atlantic: Delaware, Washington D.C., Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia. East North Central: Illinois, Indiana,
Michigan, Ohio, Wisconsin. East South Central: Alabama, Kentucky, Mississippi, Tennessee. West North Central: Iowa, Kansas, Minnesota, Missouri, Nebraska,
North Dakota, South Dakota. West South Central: Arkansas, Louisiana, Oklahoma, and Texas. Mountain: Arizona, Colorado, Idaho, Montana, Nevada, New
Mexico, Utah, Wyoming. Pacific: Alaska, California, Hawaii, Oregon, Washington
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be applicable to other commercially insured populations.
We plan to conduct future studies to address payer-level
variables that affect treatment patterns. Despite these
limitations, several research teams have conducted
important studies using similar statistical methods to
analyze data through the Optum platform, including one
study by Hershman et al. investigating socioeconomic
factors associated with adherence to breast cancer ther-
apy, [21] and another by Abraham et al. evaluating
gastrointestinal bleeding associated with different anti-
coagulant medications [22].
In future work, we expect to repeat our analyses with
longer time of follow-up and to investigate patient and
external factors that may influence patterns of treat-
ment, such as the factors that may underlie the
geographic variation we observed. Understanding the
determinants of this geographic variation is essential to
minimizing disparities in treatment delivery. We also
expect to repeat this work in broader reaching datasets
such as Medicare in order to investigate patterns of care
in patients who may not be able to afford private health
insurance. As recommendations for using these focus
drugs expand, [23, 24] identifying treatment variation
and determinants of that variation, geographical or
otherwise, become even more important so that imple-
mentation of best practices in the use of these treat-
ments across the country can be optimized and tailored
to different regions and practices.
Conclusion
In summary, we were able to identify the patterns of use
of novel agents for advanced prostate cancer and dem-
onstrate that abiraterone and enzalutamide have largely
replaced intravenous therapy docetaxel as the first-line
treatment of advanced prostate cancer. We also
observed significant geographic variation in use of treat-
ments for advanced prostate cancer. Describing this
current landscape of treatment use is the first step in
understanding treatment variation so that our future
studies can identify patient and provider characteristics
associated with variation and investigate the comparative
effectiveness of treatment outcomes in order to identify
highest value care.
Additional file
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